Registration number: 05644964

Biosynth Europe Ltd

Contents

Company Information	1
Accountants' Report	2
Balance Sheet	3
Notes to the Unaudited Financial Statements	4 to 7

Biosynth Europe Ltd

Company Information

Director

Mr P Meili

Company secretary

Mr P Meili

Registered office

5 Brayford Square London E1 0SG

Accountants

Stanmore Accountants Ltd Chartered Certified Accountants25 Rocklands Drive Stanmore Middlesex HA7 2JD

Chartered Certified Accountants' Report to the Director on the Preparation of the Unaudited Statutory Accounts of
Biosynth Europe Ltd
for the Year Ended 31 December 2024

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of Biosynth Europe Ltd for the year ended 31 December 2024 as set out on pages 3 to 7 from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Association of Chartered Certified Accountants, we are subject to its ethical and other professional requirements which are detailed at https://www.accaglobal.com/gb/en/member/standards/rules-and-standards/rulebook.html.

This report is made solely to the Board of Directors of Biosynth Europe Ltd, as a body, in accordance with the terms of our engagement letter dated 29 February 2024. Our work has been undertaken solely to prepare for your approval the accounts of Biosynth Europe Ltd and state those matters that we have agreed to state to the Board of Directors of Biosynth Europe Ltd, as a body, in this report in accordance with the requirements of the Association of Chartered Certified Accountants as detailed at http://www.accaglobal.com/gb/en/technical-activities/technical-resources-search/2009/
october/factsheet-163-audit-exempt-companies.html. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Biosynth Europe Ltd and its Board of Directors as a body for our work or for this report.

It is your duty to ensure that Biosynth Europe Ltd has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and loss of Biosynth Europe Ltd. You consider that Biosynth Europe Ltd is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the accounts of Biosynth Europe Ltd. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts.

......................................

Stanmore Accountants Ltd
Chartered Certified Accountants
25 Rocklands Drive
Stanmore
Middlesex
HA7 2JD

17 January 2025

Biosynth Europe Ltd

(Registration number: 05644964)
Balance Sheet as at 31 December 2024

	Note	2024 £	2023 £
Fixed assets
Intangible assets	4	1,621	1,891
Current assets
Debtors	5	5,781	5,670
Creditors: Amounts falling due within one year	6	(7,370)	(7,451)
Net current liabilities		(1,589)	(1,781)
Net assets		32	110
Capital and reserves
Called up share capital	7	1,000	1,000
Retained earnings		(968)	(890)
Shareholders' funds		32	110

For the financial year ending 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

For the financial year ending 31 December 2024 the company was entitled to exemption from audit under section 479A of the Companies Act 2006 relating to subsidiary companies.

Director's responsibilities:

•	The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
•	The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 17 January 2025
 

......................................... Mr P Meili Company secretary and director

Biosynth Europe Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

1	General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
5 Brayford Square
London
E1 0SG

These financial statements were authorised for issue by the director on 17 January 2025.

2	Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention.

Going concern

The financial statements have been prepared on a going concern basis.

Foreign currency transactions and balances

Transactions in foreign currencies are recorded at the rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated at the rate of the exchange ruling at the balance sheet date. All differences are taken to the profit and loss account.

Tax

The tax expense for the period comprises deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Biosynth Europe Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Intangible assets

Separately acquired trademarks and licences are shown at historical cost.

Trademarks, licences (including software) and customer-related intangible assets acquired in a business combination are recognised at fair value at the acquisition date.

Trademarks, licences and customer-related intangible assets have a finite useful life and are carried at cost less accumulated amortisation and any accumulated impairment losses.

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class	Amortisation method and rate
Trademarks, patents and licences	4% of cost per annum

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

3	Staff numbers

The average number of persons employed by the company (including the director) during the year, was 0 (2023 - 0).

Biosynth Europe Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

4	Intangible assets

	Trademarks, patents and licenses  £	Total £
Cost or valuation
At 1 January 2024	6,752	6,752
At 31 December 2024	6,752	6,752
Amortisation
At 1 January 2024	4,861	4,861
Amortisation charge	270	270
At 31 December 2024	5,131	5,131
Carrying amount
At 31 December 2024	1,621	1,621
At 31 December 2023	1,891	1,891

5

Debtors

Current	Note	2024 £	2023 £
Amounts owed by related parties		5,141	5,035
Other debtors		640	635
		5,781	5,670

6

Creditors

Creditors: amounts falling due within one year

	Note	2024 £	2023 £
Due within one year
Amounts owed to group undertakings and undertakings in which the company has a participating interest		6,409	6,502
Accruals and deferred income		961	949
		7,370	7,451

Biosynth Europe Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

7	Share capital

Allotted, called up and fully paid shares

	2024		2023
	No.	£	No.	£
Ordinary shares of £1 each	1,000	1,000	1,000	1,000

8	Parent and ultimate parent undertaking

The company's immediate parent undertaking is Biosynth Holding AG, a company registered in Switzerland. The ultimate parent undertaking is Biosynth Group Limited, a company registered in England
and Wales.

The smallest and largest group in which these financial statements are consolidated is Biosynth Group Limited, a company registered in England and Wales. The registered office of Biosynth Group Limited is
Axis House High Street, Compton, Newbury, England, RG20 6NL. The financial statements of Biosynth Group Limited are publicly available from Companies House.